Will a change at the top of the US Securities and Exchange Commission mean that drug makers will not be so readily fined for paying bribes overseas as they seek to boost sales of their medicines?
Such speculation emerged after the Trump transition team last week tapped Jay Clayton, a partner at the Sullivan & Cromwell law firm, to head the agency. And the chatter about his views on the Foreign Corrupt Practices Act stems from a 2011 paper written by a New York City Bar Association committee, which he chaired, that maintained the law was causing “lasting harm” to US companies.
About the Author Reprints
